AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4.4 Million Registered Direct Offering
Lantern Pharma (NASDAQ: LTRN) announced the closing of its previously announced registered direct offering, raising approximately $4.4 million in gross proceeds through the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share. In a concurrent private placement, the company also issued unregistered warrants to purchase up to 2,135,923 additional shares at an exercise price of $2.27 per share, which could generate up to approximately $4.85 million in additional gross proceeds if fully exercised. To view the full press release, visit https://ibn.fm/Oh6jI ABOUT LANTERN PHARMA INC. Lantern Pharma Inc. (Nasdaq: LTRN) is a…